BHV-1530

Biohaven Therapeutics Ltd. · Phase 1 active Small molecule

At a glance

Generic name	BHV-1530
Also known as	AMB302
Sponsor	Biohaven Therapeutics Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BHV-1530 CI brief — competitive landscape report
BHV-1530 updates RSS · CI watch RSS
Biohaven Therapeutics Ltd. portfolio CI